Zuclopenthixol AcetateThird Party Manufacturing in India

Zuclopenthixol Acetate works by blocking post-synaptic dopamine D1 and D2 receptors within the mesolimbic and mesocortical pathways in the brain. This strong dopaminergic blockade reduces acute psychotic symptoms and calms psychomotor agitation. Unlike ultra-long-acting decanoate esters, its specific acetate esterification provides rapid onset with an intermediate duration of action spanning 2 to 3 days, making it ideal for managing acute psychotic crises. It is highly effective and well-tolerated under close psychiatric supervision.

Therapeutic Uses

• Acute Psychosis: Rapidly manages severe episodes of acute schizophrenia and related manic phases.
• Behavioral Agitation: Quiets severe, dangerous psychomotor agitation in patients who refuse oral medications.

Why Manufacturers Choose Zuclopenthixol Acetate

Utilizing Zuclopenthixol Acetate third party manufacturing in India enables companies to enter specialized neuro-psychiatry markets. Celesta Healthcare helps clients scale production by ensuring our partner facilities are WHO-GMP certified and specialized in manufacturing oil-based, non-aqueous sterile injectables. This formulation style preserves the active compound under CAS number 85721-05-7 for intermediate clinical release. Strict adherence to WHO-GMP protocols provides excellent clarity, safety, and reliable bioavailability profiles, making your brand highly competitive in neuropsychiatric healthcare channels.